Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,902 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis.
Ruperto N, Brunner HI, Ramanan AV, Horneff G, Cuttica R, Henrickson M, Anton J, Boteanu AL, Penades IC, Minden K, Schmeling H, Hufnagel M, Weiss JE, Pardeo M, Nanda K, Roth J, Rubio-Pérez N, Hsu JC, Wimalasundera S, Wells C, Bharucha K, Douglass W, Bao M, Mallalieu NL, Martini A, Lovell D, Benedetti F; Paediatric Rheumatology INternational Trials Organisation (PRINTO) and the Paediatric Rheumatology Collaborative Study Group (PRCSG). Ruperto N, et al. Among authors: roth j. Rheumatology (Oxford). 2021 Oct 2;60(10):4568-4580. doi: 10.1093/rheumatology/keab047. Rheumatology (Oxford). 2021. PMID: 33506875 Free PMC article. Clinical Trial.
Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis.
De Benedetti F, Brunner HI, Ruperto N, Kenwright A, Wright S, Calvo I, Cuttica R, Ravelli A, Schneider R, Woo P, Wouters C, Xavier R, Zemel L, Baildam E, Burgos-Vargas R, Dolezalova P, Garay SM, Merino R, Joos R, Grom A, Wulffraat N, Zuber Z, Zulian F, Lovell D, Martini A; PRINTO; PRCSG. De Benedetti F, et al. N Engl J Med. 2012 Dec 20;367(25):2385-95. doi: 10.1056/NEJMoa1112802. N Engl J Med. 2012. PMID: 23252525 Free article. Clinical Trial.
Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial.
Brunner HI, Ruperto N, Zuber Z, Keane C, Harari O, Kenwright A, Lu P, Cuttica R, Keltsev V, Xavier RM, Calvo I, Nikishina I, Rubio-Pérez N, Alexeeva E, Chasnyk V, Horneff G, Opoka-Winiarska V, Quartier P, Silva CA, Silverman E, Spindler A, Baildam E, Gámir ML, Martin A, Rietschel C, Siri D, Smolewska E, Lovell D, Martini A, De Benedetti F; Paediatric Rheumatology International Trials Organisation PRINTO; Pediatric Rheumatology Collaborative Study Group (PRCSG). Brunner HI, et al. Ann Rheum Dis. 2015 Jun;74(6):1110-7. doi: 10.1136/annrheumdis-2014-205351. Epub 2014 May 16. Ann Rheum Dis. 2015. PMID: 24834925 Free PMC article. Clinical Trial.
MRP8/14 serum levels as diagnostic markers for systemic juvenile idiopathic arthritis in children with prolonged fever.
Park C, Miranda-Garcia M, Berendes R, Horneff G, Kuemmerle-Deschner J, Ganser G, Huppertz HI, Minden K, Haas JP, Jansson AF, Borte M, Schuetz C, Oommen P, Frosch M, Schlueter B, Richter-Unruh A, Kessel C, Hinze C, Wittkowski H, Roth J, Foell D, Holzinger D. Park C, et al. Among authors: roth j. Rheumatology (Oxford). 2022 Jul 6;61(7):3082-3092. doi: 10.1093/rheumatology/keab729. Rheumatology (Oxford). 2022. PMID: 34559193
Childhood Arthritis and Rheumatology Research Alliance consensus treatment plans for new-onset polyarticular juvenile idiopathic arthritis.
Ringold S, Weiss PF, Colbert RA, DeWitt EM, Lee T, Onel K, Prahalad S, Schneider R, Shenoi S, Vehe RK, Kimura Y; Juvenile Idiopathic Arthritis Research Committee of the Childhood Arthritis and Rheumatology Research Alliance. Ringold S, et al. Arthritis Care Res (Hoboken). 2014 Jul;66(7):1063-72. doi: 10.1002/acr.22259. Arthritis Care Res (Hoboken). 2014. PMID: 24339215 Free PMC article.
IL1RN Variation Influences Both Disease Susceptibility and Response to Recombinant Human Interleukin-1 Receptor Antagonist Therapy in Systemic Juvenile Idiopathic Arthritis.
Arthur VL, Shuldiner E, Remmers EF, Hinks A, Grom AA, Foell D, Martini A, Gattorno M, Özen S, Prahalad S, Zeft AS, Bohnsack JF, Ilowite NT, Mellins ED, Russo R, Len C, Oliveira S, Yeung RSM, Rosenberg AM, Wedderburn LR, Anton J, Haas JP, Rösen-Wolff A, Minden K, Szymanski AM; INCHARGE Consortium; Thomson W, Kastner DL, Woo P, Ombrello MJ. Arthur VL, et al. Arthritis Rheumatol. 2018 Aug;70(8):1319-1330. doi: 10.1002/art.40498. Epub 2018 Jun 28. Arthritis Rheumatol. 2018. PMID: 29609200 Free PMC article.
Phagocyte-specific S100 proteins and high-sensitivity C reactive protein as biomarkers for a risk-adapted treatment to maintain remission in juvenile idiopathic arthritis: a comparative study.
Gerss J, Roth J, Holzinger D, Ruperto N, Wittkowski H, Frosch M, Wulffraat N, Wedderburn L, Stanevicha V, Mihaylova D, Harjacek M, Len C, Toppino C, Masi M, Minden K, Saurenmann T, Uziel Y, Vesely R, Apaz MT, Kuester RM, Elorduy MJ, Burgos-Vargas R, Ioseliani M, Magni-Manzoni S, Unsal E, Anton J, Balogh Z, Hagelberg S, Mazur-Zielinska H, Tauber T, Martini A, Foell D; Paediatric Rheumatology International Trials Organization (PRINTO). Gerss J, et al. Among authors: roth j. Ann Rheum Dis. 2012 Dec;71(12):1991-7. doi: 10.1136/annrheumdis-2012-201329. Epub 2012 Jun 11. Ann Rheum Dis. 2012. PMID: 22689317 Clinical Trial.
Access to biologic therapies in Canada for children with juvenile idiopathic arthritis.
Leblanc CM, Lang B, Bencivenga A, Chetaille AL, Dancey P, Dent P, Miettunen P, Oen K, Rosenberg A, Roth J, Scuccimarri R, Tse SM, Benseler S, Cabral DA, Campillo S, Chédeville G, Duffy CM, Duffy KW, Haddad E, Huber AM, Laxer R, Levy D, Johnson N, Ramsey S, Shiff N, Schmeling H, Schneider R, Stringer E, Yeung RS, Tucker LB. Leblanc CM, et al. Among authors: roth j. J Rheumatol. 2012 Sep;39(9):1875-9. doi: 10.3899/jrheum.120089. Epub 2012 Aug 1. J Rheumatol. 2012. PMID: 22859344
4,902 results